Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment

Data from Spherix's second annual Patient Chart Dynamix™: C3G (EU5) study captured the perspectives of 148 nephrologists (located in the United Kingdom, Germany, Italy, Spain, and France) regarding the urgent need for effective treatments, as well as how their treatment approach for C3G patients has evolved. Physicians emphasized the importance of early intervention for successful patient outcomes, yet many find C3G more challenging to diagnose compared to other glomerular diseases. Despite these shifts in ...